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Background. Pro-inflammatory cytokines like interleukin
(IL)-1b and tumor necrosis factor-a (TNF-a) are believed to play
a significant role in dialysis-related morbidity. It has been previ-
ously demonstrated that the endogenous synthesis of interleukin-1
receptor antagonist (IL-1Ra) is a reliable marker of the level of
IL-1b synthesis in hemodialysis (HD) patients. In this study, we
assessed the impact of clinical and laboratory variables on IL-1Ra
synthesis by peripheral blood mononuclear cells (PBMC) in
patients on HD with unsubstituted cellulose dialyzers.
Methods. IL-1Ra by PBMC was measured by a specific non-
cross-reactive radioimmunoassay. Day to day variation in cytokine
synthesis, the correlation between cytokine synthesis under differ-
ent in vitro stimulatory conditions, and the influence of clinical
and laboratory variables on cytokine synthesis were studied.
Results. Although there was a trend towards greater IL-1Ra
synthesis by unstimulated, endotoxin-stimulated and IgG-stimu-
lated PBMC drawn before the second and third dialysis sessions
of the week when compared to the first dialysis treatment, this was
not statistically significant. There was a strong correlation be-
tween IL-1Ra synthesis by PBMC cultured under different stim-
ulatory conditions that was best observed between IL-1Ra cell
content and from endotoxin-stimulated PBMC (r 5 0.51, P 5
0.0001), and endotoxin- and IgG-stimulated PBMC (r 5 0.44, P 5
0.0001). In addition, there was a close correlation between total
synthesis (cell associated and secreted) and secreted levels of
IL-1Ra in unstimulated (r 5 0.59, P 5 0.0001) and endotoxin-
stimulated PBMC (r 5 0.69, P 5 0.0001). Interestingly, there was
an inverse correlation between IL-1Ra synthesis and duration of
dialysis that was strongest for secreted IL-1Ra from unstimulated
(r 5 20.50, P 5 0.002) and endotoxin-stimulated PBMC (r 5
20.34, P 5 0.04). There was no significant correlation between
IL-1Ra synthesis by PBMC and other clinical and laboratory
indices.
Conclusions. The observations from this study indicate that: (1)
in HD patients, there were no significant differences in cytokine
synthesis by PBMC drawn before the three different dialysis
treatments during the week; (2) there is a close relationship
between IL-1Ra synthesis from PBMC cultured under different
stimulatory conditions; (3) the secreted levels of IL-1Ra correlate
directly with total synthesis (cell-associated and secreted); (4) with
the exception of duration of dialysis, none of the other clinical or
laboratory parameters correlated with cytokine synthesis; and (5)
the diminished endotoxin- or IgG-stimulated IL-1Ra synthesis
with increasing time on dialysis is possibly another sign of the
impaired host-defense system in patients on long-term hemodial-
ysis.
During hemodialysis, human blood leukocytes are ex-
posed to several extraneous challenges: the surface mate-
rial of the dialyzer membrane and tubing, plasma products
activated by the dialyzer materials, and substances (solutes
and microbial products) from the dialysate. These interac-
tions can induce the synthesis of mononuclear cell prod-
ucts, such as pro-inflammatory cytokines, as well as their
specific inhibitors [1]. The synthesis of these monocyte/
macrophage-derived pro-inflammatory cytokines during
hemodialysis (HD) has been incriminated in the short- and
long-term morbidity experienced by HD patients [2–4].
Indeed, plasma levels of a variety of pro-inflammatory
cytokines such as interleukin-1 (IL-1) and tumor necrosis
factor (TNF) are elevated in patients on HD [5]. Further-
more, some, but not all studies have reported a further
increase in circulating levels of cytokines during the course
of a hemodialysis treatment. The reasons for variability
among these studies relates to different methodological
and biological factors that affect the measurement of
cytokines in HD patients, which have been discussed
elsewhere [5]. Suffice it to state that plasma levels of
cytokines do not necessarily reflect cytokine synthesis in
HD patients or inflammatory states.
Measurement of cytokine synthesis by peripheral blood
mononuclear cells (PBMC) probably offers a consistent
method of assessing cytokine production in dialysis pa-
tients. Transcriptional activation of interleukin-1b (IL-1b)
in PBMC has been observed following a single passage
through a unsubstituted cellulose dialyzer [6]. Conse-
quently, PBMC isolated from patients on chronic HD
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demonstrate increased spontaneous IL-1 synthesis on incu-
bation, despite the absence of exogenous stimuli [7]. In
contrast, in mononuclear cells isolated from healthy sub-
jects, neither IL-1b protein nor mRNA for IL-1b are
demonstrated by using Northern hybridization, and these
cells fail to show evidence of IL-1b synthesis even after
incubation for 24 hours [8]. Furthermore, PBMC from HD
patients are ‘primed’ to produce increased levels of IL-1b
and TNF upon in vitro stimulation [9–11]. When stimulated
with endotoxin, these cells synthesize as much as fivefold
more IL-1 as compared to mononuclear cells from healthy
subjects [7]. Similar results have been reported for the
synthesis of TNF and IL-6 [12, 13].
The interleukin-1 (IL-1) family consists of three struc-
turally related polypeptides [14]. Of these, interleukin-1a
(IL-1a) and IL-1b are pro-inflammatory and play an im-
portant role in infection and inflammation. The third
member of the interleukin-1 family, IL-1 receptor antago-
nist (IL-1Ra), is a 17 kD polypeptide that shows a 41%
conserved homology to IL-1b (30% to IL-1a) [15–17].
These cytokines act on two distinct types of cell surface
receptors. The type I receptor (IL-1RI) is found on most
cells, and the type II receptor (IL-1RII) is found primarily
on neutrophils, monocytes, bone marrow cells and B-cells
[14]. On IL-1RI, IL-1Ra has nearly the same affinity as
IL-1a or IL-1b, but lacks agonist activity. IL-1Ra compet-
itively binds to IL-1 receptors, preventing IL-1 binding and
therefore the biological responses to IL-1 [15–17].
We have previously shown that in patients on HD, the
cell content of IL-1Ra in freshly harvested PBMC as well as
the synthesis of IL-1Ra from endotoxin-stimulated PBMC
was severalfold higher than in undialyzed patients with
end-stage renal disease (ESRD), patients on continuous
ambulatory peritoneal dialysis (CAPD) or healthy controls
[18]. In addition, endotoxin-stimulated PBMC from all
three groups of patients with renal failure synthesized
significantly more IL-1Ra than IL-1b [18]. We have also
shown that synthesis of IL-IRa by PBMC was strongly
correlated with that of IL-1b by the same cells [19].
However, whether the increased IL-1Ra synthesis among
HD patients represents an adequate inhibitory response to
dialysis-induced IL-1b or is merely a ‘footprint’ of IL-1b
synthesis, remains conjectural. The latter is probably more
likely given that a relatively low receptor occupancy is
sufficient to induce an IL-1 response. Consequently, a large
molar excess of IL-1Ra is required to block the biological
responses to IL-1 [16]. Therefore, the increased synthesis of
IL-1Ra demonstrated in the above studies probably repre-
sents a sensitive marker of IL-1 synthesis, rather than an
adequate blocking response.
In the present study, we sought to “profile” cytokine
synthesis by PBMC in patients on HD with unsubstituted
cellulose membranes, using IL-1Ra as the read-out. In
particular, we examined day to day variations in IL-1Ra
synthesis by PBMC, the correlation between cytokine syn-
thesis by PBMC cultured under different in vitro stimula-
tory conditions, and the relationship between cytokine
synthesis and the clinical and laboratory indices that may
influence this process.
METHODS
Patient selection
The study was conducted at the out-patient dialysis unit
at St. Elizabeth’s Medical Center (Boston, MA, USA) and
was restricted to patients undergoing chronic HD with
unsubstituted cellulose dialyzers (Terumo Corporation,
Tokyo, Japan) reprocessed with glutaraldehyde (0.8%) and
sodium hypochlorite (,1%) using an automated system
(DRS4y; Seratronics Inc., Concord, CA, USA). Clinical
records of 107 patients were reviewed by a single observer
(SNN). Fifteen patients on dialysis using dialyzers other
than unsubstituted cellulose and five that were likely to
move or undergo renal transplantation in the near future
were excluded. Also excluded were 47 patients with condi-
tions that could influence cytokine synthesis such as acute
infection or blood transfusions in the preceding month,
chronic infections (hepatitis B, hepatitis C, human immu-
nodeficiency virus, osteomyelitis), active immunological
disease (systemic lupus erythematosus, rheumatoid arthri-
tis), immunosuppressive therapy, previous transplantation
or history of malignancy. Finally, all patients were screened
for cell content of IL-1Ra, and three patients in whom the
cell content of IL-1Ra was less than 80 pg/2.5 3 106 PBMC
were excluded from the study. The remaining 37 patients
constituted the study group. These patients were drawn
from a previous study assessing the impact of single use
versus reuse of cellulose dialyzers on clinical parameters
and indices of biocompatibility, the results of which have
been previously published [20].
Clinical indices
Clinical records were reviewed for patient characteristics
including age, gender, cause of ESRD and duration of
dialysis; type of vascular access, blood flow and episodes of
access malfunction requiring surgical intervention in the
preceding year; surface area of the dialyzer, dialysis time
(hours/week) and urea reduction ratios (URR) over the
preceding three months; and indices of patient morbidity
such as number of units of blood transfused in the preced-
ing three months, days of hospitalization in the past year,
and number of systemic infections in the past year. In
addition, the list of medications and laboratory test data
during the previous month including hematocrit, white
blood cell (WBC) count, serum calcium, phosphorous,
cholesterol, triglycerides, total protein and albumin results
were recorded. The information on these variables has
been previously published [20].
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Blood collection
In patients on hemodialysis, 10 ml of blood was drawn
into a heparinized syringe, from the fistula needle immedi-
ately following venipuncture, prior to the start of dialysis
during each of three treatments in a single week.
In vitro synthesis of IL-1Ra by peripheral blood
mononuclear cells
Water and tissue culture media used in this study were
subjected to ultrafiltration using a polyamide hollow-fiber
ultrafilter (U2000; Gambro AB, Hechingen, Germany) to
remove cytokine-inducing agents [21]. PBMC were har-
vested as previously described [18, 22]. Briefly, each 10 ml
sample of blood was diluted with 20 ml of sterile pyrogen-
free normal saline (Abbott Laboratories, Rockford, IL,
USA) and underlayered with 10 ml of Ficoll-Hypaque. The
tube was then centrifuged at 450 g for 45 minutes at room
temperature. The PBMC layer was harvested, washed in
saline and centrifuged at 400 g for 10 minutes. PBMC were
washed in saline two additional times, and resuspended in
ultrafiltered tissue culture medium (RPMI 1640, pH 7.4;
Sigma Chemical Co., St. Louis, MO, USA), containing 10
mmol/liter L-glutamine, 24 mmol/liter NaHCO3 (Mallinck-
rodt, Paris, KY, USA), 10 mmol/liter HEPES (Sigma), 100
U/ml penicillin and 100 mg/ml streptomycin (Irvine Scien-
tific, Santa Ana, CA, USA). PBMC were counted using a
standard hemocytometer and adjusted to 5 3 106 cells/ml in
RPMI. A 0.5 ml suspension of PBMC was aliquoted into
each of six 12 3 75 mm polypropylene tubes (Becton
Dickinson, NJ, USA). Tubes #1, #2 and #3 received 0.5 ml
RPMI, tubes #4 and #5 received 0.5 ml RPMI containing
20 ng/ml endotoxin (E. coli, serotype O55:B5; Sigma), and
tube #6 received 0.5 ml of RPMI containing 20 mg/ml
human immunoglobulin IgG (Gammagard; Hyland Labo-
ratories, Duarte, CA, USA). Tube #1 was immediately
frozen at 270°C for measurement of cell content of IL-1Ra
(cell content). The remaining five tubes (#2 to #6) were
incubated upright in a humidified atmosphere at 37°C with
5% CO2. At the end of 24 hours, the cell suspensions in
tubes #2, #4 and #6 were subjected to three freeze-thaw
(270°C) cycles for measurement of total IL-1Ra synthesis
(cell-associated and secreted). Tubes #3 and #5 were
centrifuged and the supernatant separated for measure-
ment of secreted IL-1Ra levels. All PBMC separations
were performed by a single individual.
Undiluted or diluted samples were assayed in radioim-
munoassay buffer (0.01 mol/liter phosphate-buffered sa-
line, pH 7.4, 0.25% bovine serum albumin and 0.05%
sodium azide), and IL-1Ra synthesis determined by a
specific non-cross-reactive radioimmunoassay [22]. The IL-
1Ra concentrations were then read from a logit plot of
percent specific binding versus the log of known concen-
trations of IL-1Ra from the linear portion of the curve
(usually between 35% and 85% specific binding). The lower
limit of detection of the radioimmunoassay for IL-1Ra was
80 pg/ml. To eliminate inter-assay variability, all samples
from each culture condition were tested in a single assay.
IL-1Ra synthesis by PBMC is expressed as pg/2.5 3 106
PBMC. Results are expressed as mean 6 standard error of
mean.
Statistical analysis
To evaluate the relationship between IL-1Ra synthesis by
PBMC under different stimulatory conditions, we used six
measurements for each patient over a three month period.
The Pearson test was used to study the correlation (R) and
statistical significance (P) of the data. Analysis of variance
(ANOVA) for repeated measures was used to detect
differences in IL-1Ra synthesis by PBMC harvested before
the three dialysis treatments during a single week. Two sets
of data were used for each patient. Based on the fact that
there were no significant differences in IL-1Ra synthesis by
PBMC drawn before the three different dialysis treatments,
the mean of three IL-1Ra measurements in a single week
was used to study the relationship between IL-1Ra synthe-
sis by PBMC and different clinical and laboratory charac-
teristics. We used the Wilcoxon test for discrete variables
and the Spearman test for continuous variables. Analyses
were run in SAS/Stat (SAS Institute Inc., Cary, NC, USA)
and Splus for DOS 2.0 (Statistical Sciences Inc., Seattle,
WA, USA). Statistical significance was defined as P , 0.05.
RESULTS
IL-1Ra synthesis by PBMC before the three HD
treatments during a single week
Although there was a trend towards greater IL-1Ra
synthesis by unstimulated, endotoxin-stimulated and IgG-
stimulated PBMC drawn before the second and third
dialysis sessions of the week (two day intervals) when
compared to the first dialysis treatment of the week (three
day interval), the differences did not reach statistical sig-
nificance.
Correlation between IL-1Ra synthesis by PBMC cultured
under different stimulatory conditions.
Table 1 shows the correlations among PBMC IL-1Ra
content, total synthesis by unstimulated, endotoxin-stimu-
lated and IgG-stimulated PBMC and total synthesis (cell
associated and secreted) and secreted levels of IL-1Ra in
unstimulated and endotoxin-stimulated PBMC. There was
a close and consistent correlation between IL-1Ra synthesis
by PBMC cultured under different stimulatory conditions,
and was best observed between IL-1Ra cell content and
total endotoxin-stimulated PBMC (r 5 0.51, P 5 0.0001;
Fig. 1), and between endotoxin- and IgG-stimulated PBMC
(r 5 0.44, P 5 0.0001). In addition, there was a close
correlation between total synthesis and secreted levels of
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IL-1Ra by unstimulated (r 5 0.59, P 5 0.0001) and
endotoxin-stimulated PBMC (r 5 0.69, P 5 0.0001; Fig. 2).
Relationship between IL-1Ra synthesis by PBMC
cultured under different stimulatory conditions and
clinical characteristics, laboratory indices and
medications
There was an inverse correlation between duration of
dialysis and total IL-1Ra synthesis (cell associated and
secreted) by unstimulated (r 5 20.26, P 5 0.13), endotox-
in-stimulated (r 5 20.31, P 5 0.07) and IgG-stimulated
(r 5 20.44, P 5 0.008; Fig. 3) PBMC. For both unstimu-
lated and endotoxin-stimulated PBMC, the inverse corre-
lation between duration of dialysis and IL-1Ra synthesis
was stronger for secreted IL-1Ra than total IL-1Ra synthe-
sis. Indeed, the inverse correlation with duration of dialysis
was stronger for secreted IL-1Ra in unstimulated PBMC
(r 5 20.50, P 5 0.002) compared to total (r 5 20.26, P 5
0.13) and for secreted IL-1Ra in endotoxin-stimulated
PBMC (r 5 20.34, P 5 0.04) compared to total (r 5 20.31,
P 5 0.07).
However, IL-1Ra synthesis by PBMC under different
culture conditions was not significantly associated with
other clinical characteristics, dialysis prescription, number
of blood transfusions, days of hospitalization or systemic
infections. In addition, IL-1Ra synthesis by PBMC was also
not significantly related to medications or laboratory indi-
ces.
DISCUSSION
In the present study, we examined day to day variations
in IL-1Ra synthesis by PBMC, the correlation between
cytokine synthesis by PBMC cultured under different in
vitro stimulatory conditions, the relationship between total
Table 1. Correlation between IL-1Ra synthesis by peripheral blood mononuclear cells (PBMC) cultured under different stimulatory conditions
Unstimulated
total
Unstimulated
secreted
Endotoxin-
stimulated total
Endotoxin-
stimulated secreted
IgG-
stimulated
Cell content
R 0.26 0.22 0.51 0.49 0.14
P 0.0002 0.002 0.0001 0.0001 0.06
Unstimulated total
R 0.59 0.25 0.29 0.15
P 0.0001 0.0005 0.0001 0.04
Unstimulated secreted
R 0.19 0.21 0.16
P 0.009 0.004 0.04
Endotoxin-stimulated total
R 0.69 0.44
P 0.0001 0.0001
Endotoxin-stimulated secreted
R 0.42
P 0.0001
The Pearson test was used to study the correlation (R) and statistical significance (P) of the data.
Fig. 1. Correlation between peripheral blood mononuclear cell (PBMC)
content of interleukin-1 receptor antagonist (IL-1Ra) and endotoxin-
stimulated IL-1Ra synthesis. r 5 0.51; P 5 0.0001.
Fig. 2. Correlation between total synthesis (cell associated and secreted)
and secreted levels of IL-1Ra in endotoxin-stimulated PBMC. r 5 0.69;
P 5 0.0001.
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cytokine synthesis and secreted levels, and the clinical and
laboratory indices that may influence cytokine synthesis.
The results indicate that among HD patients, there is a
close relationship between IL-1Ra synthesis from PBMC
cultured under different stimulatory conditions. Further-
more, secreted levels of IL-1Ra bear a direct correlation
with the total synthesis of this cytokine. There were no
significant differences in cytokine synthesis by PBMC iso-
lated before the three different dialysis treatments during
the week. Interestingly, there was a clear attenuation of
endotoxin and IgG-stimulated IL-1Ra synthesis with in-
creasing time on dialysis. Finally, with the exception of
duration of dialysis, none of the other clinical or laboratory
indices correlated with cytokine synthesis.
Interpretation of the role of cytokines in dialysis-related
morbidity is complicated by the conflicting data generated
by different studies. A partial explanation for the apparent
contradiction in the literature arises from methodological
differences in the collection and processing of specimens,
selection of patients, and variability in the assay methods
employed. We utilized PBMC harvested from patients
pre-HD in our experiments and thereby avoided the prob-
lems inherent in interpreting plasma cytokine levels, par-
ticularly the issue of diminished metabolism and clearance
of these molecules in ESRD. Water and tissue culture
media used in our experiments were subjected to ultrafil-
tration to remove cytokine-inducing agents. Furthermore, a
specific non-cross-reactive radioimmunoassay was used to
determine IL-1Ra synthesis to avoid potential interference
from a variety of inhibitors and binding proteins that may
interfere with the immunoassay. Rigorous criteria were
used in the selection of patients, and those patients with
conditions that could alter cytokine synthesis were specifi-
cally excluded from the study. Further, we excluded the
dialysis membrane as a confounding variable by restricting
the study to patients on a single dialysis membrane com-
prised of unsubstituted cellulose. Given the consistency in
the above variables, we observed a strong correlation
between IL-1Ra synthesis from PBMC cultured under
different conditions. We also observed a direct correlation
between total synthesis and secreted levels of IL-1Ra from
unstimulated and endotoxin-stimulated PBMC. However,
Haubitz and colleagues have demonstrated that the relative
amounts of IL-1b released into cell supernatants were
Fig. 3. Correlation between duration of dialysis
and IL-1Ra synthesis by endotoxin-stimulated
PBMC (A; r 5 20.31, P 5 0.07) and IgG-
stimulated PBMC (B; r 5 20.44, P 5 0.008).
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reduced in PBMC from HD patients when stimulated with
endotoxin but not Staphylococcus epidermidis [23]. There-
fore, our data do not exclude a stimulus-dependent vari-
ability in cytokine release from PBMC.
In the present study, we observed a decline in IL-1Ra
synthesis by both endotoxin-stimulated PBMC as well as
IgG-stimulated PBMC with increasing time on dialysis with
unsubstituted cellulose membranes. The reasons for the
decreased cytokine synthesis by PBMC with increasing time
on dialysis has not been clearly defined. However, some
possible hypotheses may be considered. The water used for
the preparation of dialysate is not sterile [24, 25] and the
use of bicarbonate dialysate is well known to facilitate
bacterial growth [26, 27]. Consequently, exposure to small
amounts of endotoxin or other bacterial fragments in the
dialysate may result in monocyte activation and cytokine
synthesis. However, in the long term, it is possible that
recurrent activation of these cells may lead to the down-
regulation of their ability to synthesize cytokines, similar to
the attenuation of neutrophil and monocyte function with
recurrent activation [28]. Baseline expression of CD14 on
peripheral blood monocytes has been demonstrated to be
significantly lower in HD patients compared to undialyzed
uremic patients and healthy controls [29]. Since the CD14
antigen is involved in endotoxin-induced monocyte activa-
tion, the decline in endotoxin-stimulated IL-1Ra synthesis
by PBMC could be attributed to the down-regulation of
CD14 receptors. However, the diminution in IgG-stimu-
lated IL-1Ra synthesis, which is mediated via the Fc
receptor [22], argues in favor of a more generalized defect
in cytokine synthesis by PBMC in patients on long-term
dialysis. Therefore, the attenuation of IL-1Ra synthesis by
uremic PBMC in response to IgG with increasing time on
dialysis may be a consequence of increasingly defective Fc
receptor number and/or function in patients on HD. In-
deed, Ruiz and his colleagues have demonstrated that the
clearance of IgG-coated red blood cells is impaired in
patients with chronic renal disease [30], a process mediated
by Fc receptors on splenic macrophages. In addition, these
investigators observed a defective binding of IgG-coated
red blood cells by PBMC from uremic patients [30].
Further, Zaoui and Hakim have shown that chronic dialysis
with unsubstituted cellulose dialyzers led to an attenuation
in the ability of mononuclear cells to release pro-inflam-
matory cytokines in response to a mitogen [31]. Friedlander
and colleagues have also demonstrated decreased endotox-
in-stimulated synthesis of IL-1b and TNF by mononuclear
cells in patients on chronic dialysis with cellulose dialyzers
[32]. These data and our observations are consistent with
defects in the CD14 and Fc receptors on uremic PBMC-
defects not corrected by dialysis, and which worsen with
time. Whether these defects are specific to patients dia-
lyzed with unsubstituted cellulose dialyzers is currently
unknown.
Several studies, including some from our laboratory,
have shown that HD is associated with increased synthesis
of pro-inflammatory cytokines and cytokine-specific inhib-
itory proteins. These observations and the close similarity
between the chronic complications of HD and the effects of
experimental injections of cytokines in animals or human
volunteers have lent support to the concept that heightened
cytokine synthesis during HD could contribute to morbidity
and possibly mortality in patients on long-term HD. If this
hypothesis were correct, a direct correlation between du-
ration of dialysis and cytokine synthesis would be expected.
However, the results of this study demonstrate that with
increasing time on dialysis, endotoxin or IgG-stimulated
cytokine synthesis actually declined. This paradox may be
explained by the possibility that the higher mortality among
patients with increased cytokine synthesis may have re-
sulted in long-term survivors being predominantly in the
“low cytokine producer’’ group (“left truncation’’). Proof
for this hypothesis would require a long-term follow-up of
the cohort of patients in this study and a comparison of
outcomes between the high and low cytokine producers;
this study is currently underway.
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